World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
94
Citations
61156
World Ranking
10239
National Ranking
5265

Overview

Igor Puzanov is affiliated with Roswell Park Cancer Institute in the United States. Their research activity spans multiple areas within medicine, biochemistry, genetics, and molecular biology, with a focus on oncology and immunology as primary subfields. The scientist's work intersects cancer research, molecular biology, pulmonary and respiratory medicine.

The main topics of research covered by Igor Puzanov include:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Cancer Genomics and Diagnostics
  • Melanoma and MAPK Pathways
  • Renal cell carcinoma treatment
  • Cutaneous Melanoma Detection and Management

Igor Puzanov has frequently collaborated with several researchers throughout their career. These frequent co-authors include:

  • Paolo A. Ascierto
  • Ahmad A. Tarhini
  • Marc S. Ernstoff
  • Susanne M. Arnold
  • George J. Weiner

The scientist has published extensively in various scientific venues. The most common journals and publication types include:

  • Journal of Clinical Oncology
  • Regular and Young Investigator Award Abstracts
  • Journal of Translational Medicine
  • Cancer Research
  • Journal for ImmunoTherapy of Cancer

Some of the recent notable publications by Igor Puzanov are:

  • "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events," 2021, Journal for ImmunoTherapy of Cancer
  • "COVID-19 and Cancer: a Comprehensive Review," 2020, Current Oncology Reports
  • "Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab," 2023, Journal of Clinical Oncology
  • "Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma," 2022, Journal of Clinical Oncology
  • "Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy," 2020, Annals of Oncology

Best Publications

  • Inhibition of mutated, activated BRAF in metastatic melanoma.

    Keith T. Flaherty;Igor Puzanov;Kevin B. Kim;Antoni Ribas

  • Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

    Julie R. Brahmer;Christina Lacchetti;Bryan J. Schneider;Michael B. Atkins

  • Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

    Keith T. Flaherty;Jeffery R. Infante;Adil Daud;Rene Gonzalez

  • Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

    Robert H.I. Andtbacka;Howard L. Kaufman;Frances Collichio;Thomas Amatruda

  • Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

    Suzanne L. Topalian;Mario Sznol;David F. McDermott;Harriet M. Kluger

  • Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

    Jeffrey A. Sosman;Kevin B. Kim;Lynn Schuchter;Rene Gonzalez

  • Fulminant Myocarditis with Combination Immune Checkpoint Blockade

    Douglas B. Johnson;Justin M. Balko;Margaret L. Compton;Spyridon Chalkias

  • Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF -mutant melanoma

    Gideon Bollag;Peter Hirth;James Tsai;Jiazhong Zhang

  • Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

    I. Puzanov;A. Diab;K. Abdallah;C. O. Bingham

  • Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

    David M. Hyman;Igor Puzanov;Vivek Subbiah;Jason E. Faris

  • Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

    Antoni Ribas;Igor Puzanov;Reinhard Dummer;Dirk Schadendorf

  • Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

    Antoni Ribas;Reinhard Dummer;Igor Puzanov;Ari VanderWalde

  • Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

    Hussein A. Tawbi;Peter A. Forsyth;Alain Algazi;Omid Hamid

  • RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

    Fei Su;Amaya Viros;Carla Milagre;Kerstin Trunzer

  • Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial

    Kim Margolin;Marc S Ernstoff;Omid Hamid;Donald Lawrence

  • Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

    Georgina V. Long;Uwe Trefzer;Michael A. Davies;Richard F. Kefford

  • Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

    Jason Chesney;Igor Puzanov;Frances Collichio;Parminder Singh

  • Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

    Douglas B. Johnson;Ryan J. Sullivan;Patrick A. Ott;Matteo S. Carlino

  • Adjuvant Sunitinib or Sorafenib for High-Risk, Non-Metastatic Renal-Cell Carcinoma (ECOG-ACRIN E2805): A Double-Blind, Placebo-Controlled, Randomised, Phase 3 Trial

    Naomi B. Haas;Judith Manola;Robert G. Uzzo;Keith T. Flaherty

  • Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.

    William D Tap;Zev A Wainberg;Stephen P Anthony;Prabha N Ibrahim

Frequent Co-Authors

Jeffrey A. Sosman
Jeffrey A. Sosman Northwestern University
Omid Hamid
Omid Hamid Cedars-Sinai Medical Center
Douglas B. Johnson
Douglas B. Johnson Vanderbilt University Medical Center
Antoni Ribas
Antoni Ribas University of California, Los Angeles
Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health
Michael B. Atkins
Michael B. Atkins Georgetown University
Marc S. Ernstoff
Marc S. Ernstoff Roswell Park Cancer Institute
Adil Daud
Adil Daud University of California, San Francisco
Georgina V. Long
Georgina V. Long University of Sydney
David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in Medicine doesn’t always mean you must follow the traditional path of an MD. There are several online degree options that can prepare you for rewarding healthcare careers, offering flexibility and affordability. For those seeking to advance quickly, accelerated msn psychiatric np programs can lead to highly specialized roles in mental health, allowing professionals to address urgent mental health needs across the U.S.

If you’re interested in healthcare leadership or management, a bachelors in healthcare administration is a solid foundation, while pursuing a master's in healthcare administration online opens doors to executive positions and greater responsibility within healthcare organizations.

For nurses wanting to move into the highest clinical or leadership roles, best online bsn to dnp programs offer the opportunity to achieve a doctorate in nursing practice while maintaining professional and personal commitments.

These online degrees provide accessible and practical options for aspiring healthcare professionals looking to advance their knowledge, skills, and career opportunities beyond traditional medical school pathways.

Best Scientists Citing Igor Puzanov

Trending Scientists

Recently Published Articles